Search Within

Gregory J Riely

  1. "Geoffrey Oxnard"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (9)
  3. Thoracic Oncology (9)
  4. Department of Pathology and Laboratory Medicine (5)
  5. GSK Faculty (5)
  6. Human Oncology and Pathogenesis Program (5)

More Groups

People
  1. Geoffrey Oxnard (9)
  2. Mark Kris (8)
  3. Vincent Miller (7)
  4. Camelia Sima (5)
  5. Marc Ladanyi (5)
  6. Maria Arcila (5)

More People

Years
  1. 2012 (1)
  2. 2011 (6)
  3. 2010 (1)
  4. 2009 (1)
Publications
  1. Clinical Cancer Research (4)
  2. Journal of Clinical Oncology (4)
  3. Journal of Thoracic Oncology (1)
Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (4)
  3. Elsevier Inc. (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reply to E.M. Gilles
    Journal Article

    Oxnard, G. R.; Schwartz, L. H.; Riely, G. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance
    Meeting Abstract

    Chaft, J. E.; Oxnard, G. R.; Miller, V. A.; Kris, M. G.; Sima, C. S.; Riely, G. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
    Journal Article

    Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. J.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes
    Journal Article

    Oxnard, G. R.; Zhao, B.; Sima, C. S.; Ginsberg, M. S.; James, L. P.; Lefkowitz, R. A.; Guo, P.; Kris, M. G.; Schwartz, L. H.; Riely, G. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
    Journal Article

    Oxnard, G. R.; Arcila, M. E.; Sima, C. S.; Riely, G. J.; Chmielecki, J.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Journal Article

    Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Solomon, S. B.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Miller, V. A.; Ladanyi, M.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Oxnard, G. R.; Riely, G. J.; Arcila, M. H.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Rebiopsy of patients with "acquired resistance" to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Miller, V. A.; Riely, G. J.; Arcila, M. E.; Oxnard, G.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Ladanyi, M.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save